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Summary
Mitral regurgitation (MR) is a highly prevalent condition
among elderly patients, affecting almost 10% of the gen-
eral population aged 75 and older. Left untreated, severe
MR results in high mortality and frequent hospitalisation
for treatment of heart failure. Surgical treatment remains
the first-line therapy for symptomatic, severe MR, espe-
cially for patients presenting with a primary aetiology.
However, a high proportion of patients with MR are turned
down for open-heart surgery, mainly due to advanced age,
diminished left ventricular function and comorbidities.
Thus, percutaneous treatment options have been recently
developed as an alternative. In this article, we will review
transcatheter interventional techniques at the level of the
mitral valve, including implantation technique, indications
and clinical results.
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mitral stenosis, TMVI, TMVR, mitral valve disease
Introduction
Mitral regurgitation (MR) is a highly prevalent condition
among elderly patients, affecting almost 10% of the gen-
eral population aged 75 and older [1]. From a mechanistic
point of view, MR is usually classified into two different
categories: primary (degenerative) and secondary (func-
tional) MR. The latter condition is further subdivided into
ischaemic and non-ischaemic aetiology. Degenerative mi-
tral valve (MV) disease is the most frequent mechanism of
MR (60–70%) [2] and is related to the structural modifi-
cation of the valve leaflet tissue, including prolapse, flail
leaflet and annular calcification, and the supporting appa-
ratus. Secondary MR affects patients with left ventricu-
lar dysfunction. Ventricular dilation exerts tension on the
valve leaflets via the papillary muscles and chordal appa-
ratus, resulting in leaflet tethering and subsequent loss of
coaptation.
Left untreated, severe MR results in chronic volume over-
load of the left ventricle accompanied by increased left
atrial and pulmonary artery pressure, ultimately leading
to pulmonary oedema, right ventricular dysfunction and
secondary tricuspid regurgitation. The mortality associated
with untreated severe MR is as high as 50% within five
years, with 90% of surviving patients experiencing symp-
toms of heart failure, atrial fibrillation or an indication for
MV repair or replacement [3].
In this article, we will review transcatheter interventional
techniques at the level of the MV, including implantation
technique, indications and clinical results.
Diagnosis and grading of mitral regurgitation
Although transthoracic echocardiography (TTE) is the pre-
ferred diagnostic tool to detect MR, transoesophageal
echocardiography (TEE) achieves more precise grading,
as well a better assessment of the underlying mechanism.
Evaluation of the suitability for transcatheter MV interven-
tions usually requires the acquisition of three-dimension-
al sequences used to localise the lesion, appreciate valve
anatomy and measure the 3D valve area. Table 1 sum-
marises the semi-quantitative and quantitative criteria con-
sidered for grading of MR according to the most recent
guidelines of the European Society of Cardiology [4]. The
integrative implementation of these different parameters is
expected to improve diagnostic reliability.
Surgical mitral valve repair/replacement
Surgical treatment remains the first-line therapy of symp-
tomatic, severe MR, especially for patients presenting with
primary MR. In asymptomatic patients, the presence of
atrial fibrillation, diminished left ventricular function
Table 1: Semi-quantitative and quantitative criteria for the diagnosis of
severe MR.
Semi-quantitative criteria
Vena contracta (mm) ≥7 (>8 for biplane measure-
ments*)
Pulmonary veins Systolic flow reversal
Mitral inflow Dominant E-wave ≥1.5 m/s
MR velocity (CW Doppler) TVI mitral/TVI aortic >1.4
Quantitative criteria Primary Secondary
EROA (mm2) ≥40 ≥20
Regurgitant volume (ml) ≥60 ≥30
*average from 4- and 2-chamber view
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(≤60%) and pulmonary hypertension are predictors of
worse outcomes, and thus support early correction. Surgi-
cal and clinical results are largely dependent on the un-
derlying aetiology, as well as on valve repairability. In
patients with primary valvulopathy, surgical repair is asso-
ciated with a low recurrence rate (90% of patients alive af-
ter 20 years of follow-up are free of severe MR) [5], and
observational studies suggest improved clinical outcomes
compared to MV replacement [6].
The benefit of surgical correction of secondary MR is not
well established [7, 8], and perioperative mortality remains
high despite improvements in surgical technique. Recur-
rent MR, which has been directly linked to impaired clini-
cal outcomes [9], is as high as 30% at six months [10] and
60% within two years [11]. Comparing MV repair and re-
placement for severe ischemic MR, a recently published
randomised trial reported no significant differences in mor-
tality (19.0 vs 23.2%; p = 0.39) and left ventricular reverse
remodelling at two years. Of note is that the recurrence
of moderate to severe MR was 58.8% in the repair group
compared to 3.8% in the replacement group, resulting in a
significantly higher rate of rehospitalisation for heart fail-
ure in the repair group [12].
Rationale for the development of transcatheter
valve solutions
In the past, the structural treatment of severe MR has ex-
clusively been based on surgical MV repair or replace-
ment. However, approximately 50% of patients presenting
with severe symptomatic MR are not referred for open-
heart surgery due to high operative risk (mainly related to
advanced age and impaired left ventricular function) [13].
In-hospital mortality after MV surgery in octogenarians is
as high as 13% after MV replacement and 6% after MV re-
pair [14]. Similarly, patients with diminished left ventric-
ular function (<40%) have a post-procedural mortality of
10% following valve replacement and 6% after valve re-
pair [15]. These data support the ongoing development of
less invasive procedures which are better adapted to elder-
ly patients with frequent comorbidities.
During the last few years, two methods have been de-
veloped for the percutaneous treatment of the MV: tran-
scatheter MV repair and transcatheter MV replacement.
Table 2 summarises the principal advantages of each
method.
The Heart Team, consisting of experienced cardiac sur-
geons, interventional cardiologists, imaging guiding spe-
cialists and heart failure physicians, plays a crucial role in
the decision-making process. The individual risk constel-




Transcatheter mitral valve re-
placement
High safety Standardised strategy and short pro-
cedure duration
Conservation of the native
anatomy
Predictable outcome in terms of MR
reduction
Low risk of thrombosis One system fits all anatomies (?)
Low risk of interaction with
LVOT and subvalvular appara-
tus
Durability (?)
lation is established based on medical history and comor-
bidities.
Transcatheter mitral valve repair
Contemporary transcatheter MV reconstruction systems
are categorised into three groups according to their mech-
anism of action: leaflet repair, direct, and indirect annulo-
plasty. While annuloplasty techniques are exclusively ap-
plied among patients with sectional MR, leaflet repair can
be used for the treatment of both MR categories.
Percutaneous leaflet repair: technical aspects
Edge-to-edge repair replicates a simplified surgical recon-
struction method, the Alfieri technique, that consists of
connecting the central part of the anterior and posterior
MV leaflets (A2-P2) together, thereby creating a double
orifice MV. In surgical observational studies, this method
has been shown to effectively reduce MR [16], although it
is routinely combined with annuloplasty.
Two percutaneous devices have been developed to enable
percutaneous leaflet repair.
1. The Abbott MitraClip system
The MitraClip system (Abbott, Abbott Park, Illinois) was
first implanted in a human in 2003. Five years later, in
2008, it was the first percutaneous MV therapy to receive
CE approval. FDA approval for patients with primary MR
followed in 2013. In the meantime, more than 70,000 pa-
tients have been treated worldwide.
The 24 French delivery system is introduced into the left
atrium using a transvenous, transseptal approach (fig.
1A,B). The assembly consists of an orientable guiding
catheter and a steerable clip delivery catheter (CDS). After
localisation of the target lesion, usually using 3D TEE,
the clip is orientated above it (fig. 1C,D). The device is
then introduced into the left ventricle where grasping of
the leaflet is attempted. Once both leaflets are placed on
the clip arms, the clip is closed, creating a double orifice
MV (fig. 1E,F). Leaflet insertion, residual MR, transvalvu-
lar gradient and 3D MV area are systematically assessed
before the decision to reposition or implant the device is
made.
The principal advantages of this intervention include the
minimal invasive approach, enabling rapid patient recov-
ery, along with a high safety profile. In the largest registry
to date, which investigated the outcomes of 3697 patients
treated in the USA, stroke was reported in 0.5% of patients,
bleeding complications in 3.8%, and in-hospital mortality
in 2.3% [17].
A new iteration of the MitraClip (XTR) featuring longer
arms became available in early 2018 and is intended to fa-
cilitate leaflet retention.
2. The Edwards PASCAL Transcatheter mitral valve re-
pair system
The novel Edwards PASCAL MV repair system has been
designed to address some of the technical limitations ob-
served with the MitraClip system. The device is introduced
via transseptal access using a 22 French guide sheath (fig.
2A,B), and incorporates a spacer within the MV regur-
gitant orifice. It is attached to the valve leaflets by two
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wide paddles designed to avoid concentrated stress on the
leaflets (fig. 2C,D). The system is intended to simplify
the navigation in the left atrium, improve MR reduction
through implementation of a central spacer and allow for
independent leaflet grasping with each individual arm of
the device. The latter may be important in complex
anatomical situations, e.g. in patients with calcification, re-
traction or tethering of the posterior leaflet, as well as in
the presence of a large prolapse gap (>1 cm). Preliminary
results collected in a compassionate use cohort of 23 pa-
tients were encouraging, with acute MR ≤2+ in 97% of the
patients at discharge, without elevated gradient despite the
relatively larger size of the device [18]. The device recent-
ly obtained CE approval based on the data of the CLASP
study.
Percutaneous edge-to-edge repair: the evidence
The efficacy of the MitraClip system was explored in the
first randomised trial, the EVEREST II trial, which re-
ported similar mortality throughout five years of follow-up
Figure 1: General principles of the Abbott MitraClip system. A: transseptal puncture in superior posterior position; B: 3D TEE view from the
top of the left atrium showing introduction of the clip delivery system into the left atrium; C-D: positioning of the steerable catheter above the
defect at the origin of the MR jet under 3D echocardiographic guidance (yellow arrows = mitral valve leaflets); E: grasping of the valve leaflets;
F: final result shown by 3D TEE with the clip in the middle of the valve (A2-P2), creating a double orifice (left panel view from the left atrium,
right panel from the left ventricle). LA: left atrium; LV: left ventricle; 3D: three-dimensional; TEE: transoesophageal echocardiography. The ma-
terial used for designing panels A, C and E has been used with courtesy of Abbott.
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among patients treated with the Mitraclip compared to pa-
tients treated by standard surgical mitral intervention (20.8
vs 26.8%; p = 0.4). In terms of efficacy, surgery was supe-
rior to the MitraClip in primary MR (freedom from death,
MV surgery, reintervention and moderate to severe MR at
five years in 45.5 vs 76.2% of patients; p <0.001), whereas
there was no significant difference between patients treated
for secondary MR (freedom from the same combined end-
point in 40.5% in the MitraClip group versus 28.6% in the
surgical group; p = 0.43). Overall, patients enrolled in the
MitraClip group were more likely to have relevant residual
MR requiring valve surgery during the first six months, al-
though this was no longer observed in a landmark analysis
beyond six months. These results confirm the durability of
the acute MR reduction obtained with the MitraClip sys-
tem. Importantly, in this trial only 27% of patients had sec-
ondary MR, a category of patients that has been specifical-
ly investigated in two recently published randomised trials,
MITRA-FR and COAPT.
In the French MITRA-FR study [19] 307 patients with
left ventricular dysfunction and severe secondary MR (ef-
fective regurgitant orifice area >20 mm2 or regurgitant
volume >30 ml/beat) were randomly assigned to either
transcatheter mitral edge-to-edge repair with the MitraClip
system combined with medical treatment, or medical treat-
ment alone. MR grade ≤2+ was achieved in 83% of pa-
tients at one year. The study found no difference concern-
ing the primary endpoint (all-cause death and unplanned
re-hospitalisation for heart failure at one year), which oc-
curred in 83 patients (55%) in the intervention group and
78 patients (52%) in the control group (OR, 1.16; 95%
confidence interval [CI], 0.73 to 1.84; p = 0.53). Similarly,
the mortality rate was 24.3% in the intervention group vs.
22.4% in the control group (HR in the intervention group,
1.11; 95% CI, 0.69 to 1.77) at 12 months. Unplanned
hospitalisation for heart failure occurred in 48.7% of pa-
tients in the intervention group vs 47.4% in the control
group (HR, 1.13; 95% CI, 0.81 to 1.56). Adverse events
like strokes, renal replacement therapy and bleedings were
more frequent in the intervention group.
The recently published COAPT trial [20] randomised 614
patients with symptomatic heart failure and moderate to se-
Figure 2: Procedural steps for the implantation of the Edwards PASCAL transcatheter mitral valve repair system. A: Introduction of the im-
plant into the left atrium. B: Flexion of the steerable catheter and orientation of the device towards the mitral valve. C: Attachment of the PAS-
CAL device to the mitral valve leaflets and deployment of the device. D: Spacer fills the regurgitant orifice area and minimises the tension ex-
erted on the valve leaflets. MV: mitral valve; LA: left atrium; LV: left ventricle. The material used for designing the figure has been used with
courtesy of Edwards Lifesciences.
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vere or severe secondary MR (semi-quantitative Grade 3+
or 4+ according to integrative assessment as defined by the
American Society of Echocardiography) to either guide-
line-directed medical treatment alone or transcatheter MV
repair using the MitraClip system combined with medical
therapy. The primary endpoint was the number of all hos-
pitalisations for heart failure at 24 months. Principal pow-
ered secondary endpoints included all-cause mortality at
two years, as well as change in quality of life, six minute-
walk test and left ventricular end-diastolic volume, all at
12 months. MR reduction to grade 2+ or less at 12 months
was obtained in 95% of patients. After 24 months, there
were 160 hospitalisations for heart failure in 92 patients in
the device group and 283 hospitalisations in 151 patients in
the control group, corresponding to annualised hospitalisa-
tion rates of 35.8% and 67.9% per patient-year respective-
ly. The number of patients needed to be treated to prevent
one hospitalisation was 3.1 (95% CI 1.9–7.9). In addition,
mortality at two years of follow-up was significantly lower
following MitraClip implantation (29.1 vs 46.1%; hazard
ratio, 0.62; 95% CI 0.46–0.82; p <0.001) corresponding to
a relative risk reduction of 37% and a number needed to
be treated to prevent one death of 5.9 (95% CI 3.9–11.7).
Significant improvement was also observed for each of the
nine additional pre-specified secondary endpoints.
There are important differences between both studies
which may have contributed to these divergent findings:
‒ Inclusion of patients with less severe MR but more se-
vere cardiomyopathy in MITRA-FR due to the adoption of
different definitions concerning the severity of MR, related
to the observance of the European guidelines in MITRA-
FR and the American guidelines in COAPT. The mean ef-
fective regurgitant orifice area was 0.31±0.10cm2, with a
left ventricular end diastolic volume of 135±35 ml/m2, in
MITRA-FR, and 0.41±0.15 cm2, with left ventricular end-
diastolic volume of 101±34 ml/m2, in COAPT.
‒ Less strict optimisation of the medical therapy at time of
inclusion, as well as a lack of treatment monitoring in MI-
TRA-FR may have failed to capture symptom-driven ther-
apy intensification in favour of the control group. This may
explain the improvements (including MR reduction) seen
in the medical group that were not observed in COAPT,
which did require persistent heart failure symptoms despite
optimised medical therapy.
‒ Differences in procedural results and complication rates
(14.6% in MITRA-FR versus 8.5% in COAPT), as well
as less frequent multiple clip implantations in MITRA-FR
(54% versus 62% in COAPT).
‒ Lack of power for functional and echocardiographic sec-
ondary endpoints in MITRA-FR due to loss of follow-up,
which may have masked differences between the groups.
‒ Shorter follow-up in MITRA-FR (difference in mortality
emerged only after 12 months in COAPT)
The results of both studies provide valuable guidance re-
garding patient selection for transcatheter MV repair. Each
study outlines a different category of patients with different
responses to interventional treatment.
The COAPT trial represents an important therapeutic ad-
vancement for selected patients with heart failure who
have a particularly poor prognosis under medical treatment
alone. In addition, these findings profoundly modify the
traditional pathophysiological understanding of heart fail-
ure with reduced left ventricular function. Indeed, in view
of these results, volume overload due to severe MR should
no longer be considered a simple bystander of concomitant
left ventricular disease, but rather an important mediator
of deleterious outcomes, requiring dedicated attention and
treatment.
Identification of appropriate candidates in a timely manner
implies screening for relevant MR at an early stage of
left ventricular dysfunction and periodic echocardiograph-
ic surveillance following ischaemic events.
In patients with more advanced disease, the use of tran-
scatheter MV repair in this category of patients should be
evaluated on a case-by-case basis, based on drug tolerance
and efficacy to maintain cardiac compensation.
Percutaneous direct annuloplasty
Percutaneous direct annuloplasty has been developed to
replicate surgical ring implantation and subsequent annular
reduction. It has been developed for the treatment of pa-
tients with secondary MR. Direct annuloplasty devices are
implanted into the annulus itself under echocardiographic
guidance.
The Edwards Cardioband mitral reconstruction system
The Cardioband system (Edwards Lifescience, Irvine, CA)
received CE mark approval in 2015 for the treatment of pa-
tients with secondary MR. It consists of a percutaneous an-
nular reduction device that is implanted via transseptal ac-
cess into the posterior annulus of the MV (fig. 3A). After
delivery, the length of the incomplete ring is contracted
in order to reduce the septolateral dimensions and subse-
quently improve MR (fig. 3B). Results at 12 months in
60 patients showed the feasibility of the implantation with
high technical success (97%). In terms of safety, no pro-
cedural death occurred. Life-threatening complications oc-
curred in four patients (7%; one stroke, one myocardial
infarction and one cardiac arrest, both due to circumflex
artery occlusion, one tamponade). Anchor disengagement
was observed in 10 patients (17%) leading to device in-
efficacy in five patients. Immediate MR reduction by at
least one grade was obtained in 52 patients (87%). In the
12 months following the procedure, seven patients (12%)
required a second intervention due to recurrent MR (six
transcatheter and one surgical). Considering the whole co-
hort (including the patients with re-intervention), 61% of
patients had moderate or less MR [21]. The secondary im-
plantation of an edge-to-edge repair system upon the recur-
rence of MR is feasible [22].
The Millipede IRIS complete annuloplasty ring
The Millipede IRIS transcatheter system (Boston Scien-
tific, Marlborough, MA, USA) is a semi-rigid, complete
annuloplasty ring (fig. 4A) placed via a transfemoral/
transspetal venous approach (fig. 4B). The ring is anchored
into the mitral annulus by rotating helical anchors, and
can repositioned and retrieved. Actuation of the device re-
sults in the controlled reduction of the septo-lateral diam-
eter (fig. 4C). Preliminary results in 11 patients implanted
via the transfemoral/transspetal access showed good safe-
ty and MR reduction (80% of the patients had MR grade
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0-1+ at 1 year). A reduction of the septo-lateral diameter
of more than 30% was observed. There was no mortality at
12 months. One patient in whom the Millipede device was
implanted surgically had recurrent MR 15 months after the
procedure and was treated with the implantation of a single
MitraClip into the ring [23].
Although encouraging, these preliminary results need to be
confirmed in a larger population of patients.
Percutaneous indirect annuloplasty
Percutaneous indirect annuloplasty devices are designed to
exert forces on the annulus from the outside. Most of them
are implanted into the coronary sinus.
The Carillon Mitral Contour System
The Carillon Mitral Contour System (Cardiac Dimensions,
Inc., Kirkland, WA) is implanted into the coronary sinus
via the jugular access. It consists of two helical anchors
connected by a nitinol arc, which enables self-orientation
during deployment (fig. 5). The implant aims to reduce
Figure 3: Principles of the Edwards Cardioband system. A: The Edwards Cardioband annular reduction device is introduced into the left atri-
um via the transseptal access and implanted into the posterior mitral valve annulus using 12-16 anchors; B: The length of the adjustable im-
plant is contracted to decrease the septolateral diameter and reduce mitral regurgitation. The material used for designing the figure has been
used with courtesy of Edwards Lifesciences.
Figure 4: The Millipede IRIS complete annuluploasty ring. A: The Millipede complete annuloplasty ring consists of a semi-rigid, annular ring
with a nitinol frame; B: The system is introduced via the transseptal access and secured with six screws; C: actuation of the device reduces
the mitral annular dimensions. Each screw can be steered separately allowing for differential cinching according to individual anatomy. The
material used for designing the figure has been provided by Boston Scientific.
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Figure 5: The Carillon Mitral Contour System. A: The Carillon Mitral Contour System consists of two helical anchors connected by a nitinol
arc; B: The implant design enables self-orientation during deployment into the coronary sinus. The material used for designing the figure has
been provided by Cardiac Dimensions Inc.
MR through the application of external circumferential
pressure around the annulus. Manual traction on the deliv-
ery system pulls the proximal anchor towards the coronary
sinus ostium, plicating the periannular tissue. Advantages
of this system include the short duration of the procedure,
which can be performed under local anaesthesia and with-
out echocardiographic guidance, as well as the possibili-
ty of it being easily combined with other therapy modal-
ities (e.g. MitraClip or even surgical or transcatheter MV
replacement).
The Carillon system has received CE approval for the
treatment of patients with symptomatic, severe secondary
MR and has been implanted in more than 850 patients
worldwide. The TITAN study showed reduction of MR by
30-50% at 12 months, with high peri-procedural safety and
improvement of symptoms in the majority of patients [24].
In the randomised REDUCE-FMR trial, 87 patients were
treated with the Carillon device, while 33 underwent a
sham procedure. After 12 months there was no difference
in the cumulative rates of major adverse events of both
groups, confirming the high safety of the procedure. In the
patients with the Carillon device, a limited reduction in
MR (22% of the regurgitant volume) was observed, com-
pared to a 8% increase in the sham group (p = 0.03).
The MVRx ARTO System
The aim of the MVRx ARTO system (MVRx, Inc., San
Mateo, CA) is to improve leaflet coaptation by shortening
the antero-posterior diameter of the mitral annulus. To
achieve this, the coronary sinus is cannulated from the
right internal jugular vein and a magnetic catheter is po-
sitioned behind the posterior leaflet. Using a standard
transseptal puncture from the right femoral vein, a second
magnetic catheter is introduced into the left atrium. Both
catheters are linked magnetically, allowing a thin crossing
wire to be pushed from the coronary sinus into the
transseptal catheter. After externalisation of the wire, a
loop from the right internal jugular vein to the right
femoral vein is created. Over this loop, a 3cm coronary si-
nus anchor, linked to a septal anchor by a catheter of ad-
justable length, is deployed, resulting in the reduction of
the mitral annulus and MR (fig. 6).
The latest report from the MAVERIC efficacy and safety
study [25] showed MR≤2+ in 92% of the 44 included pa-
Figure 6: The MVRx ARTO indirect annuloplasty system. The
MVRx ARTO indirect annuloplasty system aims to reduce the an-
tero-septal mitral annulus diameter through implantation of an an-
chor in the great cardiac vein (GCV), linked to a septal anchor by
an adjustable suture. The figure has been provided by MVRx, Inc.
tients at 12 months according to core lab analysis. Death
occurred in 11.4%, while 11.7% of the patients were re-
hospitalised due to heart failure symptoms. Only one pa-
tient had a reintervention during the first year. Importantly,
the MAVERIC trial enrolled a high proportion of patients
(31%) with moderate MR (2+) at baseline, with the same
proportion being in NYHA class II. This certainly corre-
sponds to a population of patients with less advanced dis-
ease compared to those treated in other, previously men-
tioned feasibility studies. These findings need to be
confirmed in a larger population of patients.
Transcatheter mitral valve replacement
Two different techniques are used for transcatheter MV
replacement in experienced centres: the implantation of a
TAVI valve, initially designed for the aortic position, and
the use of dedicated systems for the mitral position.
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Figure 7: Examples of mitral interventions using TAVI devices. A: Transfemoral/transseptal implantation of a Sapien 3 valve into a degenerat-
ed surgical mitral valve bioprosthesis; B: Transapical implantation of an Edwards Sapien XT valve into a surgical annuloplasty ring; C: valve-
in-MAC (mitral annular calcification) implantation via the transfemoral/transseptal access. LA: left atrium; LV: left ventricle; Ao: aorta; MAC: mi-
tral annular calcification
Off-label use of TAVI devices in the mitral position
Off-label use of transcatheter heart valves, initially de-
signed to be implanted in the aortic position, has emerged
as a valuable alternative to open-heart surgery in selected
patients. This includes the percutaneous delivery of a tran-
scatheter bioprosthesis into a degenerated bioprosthesis
(fig. 7A), a surgical annuloplasty ring (fig. 7B), or directly
into a concentric, calcified native mitral annulus (fig. 7C).
Early data show haemodynamic and clinical efficacy of
these interventions using either the transapical or, prefer-
ably, the transfemoral/transseptal access [26]. The second
approach has the advantage of being less invasive, since
no surgical access is required. Valve-in-valve implantation
has the highest device success and the lowest mortality
rate at 30 days (5.7%), whereas valve-in-ring implantation
is more frequently associated with residual MR (19.4 vs
6.8%; p = 0.003), as well as second valve implantation
(11.1 vs 2.8%; p = 0.008) [27]. The periprocedural risk
is highest during valve-in-native-annulus implantation
(valve-in-MAC), mainly due to the risk of left ventricular
outflow tract (LVOT) obstruction (almost 10%), as well as
acute or delayed valve embolisation, usually into the left
atrium [28]. The increased risk of valve thrombosis ob-
served in the mitral position renders oral anticoagulation
mandatory in all patients, irrespective of the intervention
type.
Transcatheter mitral valve implantation (TMVI)
Although no dedicated transcatheter MV replacement sys-
tem has been approved for commercial use yet, numerous
devices are currently under preclinical or clinical investi-
gation. They differ mainly in anchoring mechanisms and
access (fig. 8). Although few devices rely exclusively on
intrinsic radial force, the majority of devices deploys an-
chors that grasp the leaflets, the subvalvular apparatus or
the trigone itself. In addition, some devices (Caisson and
Tiara) have the ability to immobilise the anterior leaflet in
order to avoid its displacement into the LVOT, and thus
prevent LVOT obstruction.
After the initial development of systems using the transapi-
cal access, efforts are currently being made to miniaturise
and modify them for implantation via the less invasive
transfemoral/transseptal approach. This may be particular-
ly relevant in patients with secondary MR, in whom the
transapical access has been shown to result in increased
bleeding complications and mortality.
Table 3 summarises the early results of the most frequently
implanted systems. In contrast to transcatheter valve re-
pair, MV replacement usually results in the complete reso-
lution of MR. However, several specific safety aspects re-
quire further investigations, including the most appropriate
antithrombotic management to prevent valve thrombosis,
adequate patient selection based on LVOT anatomy, inter-
action with a previously implanted aortic prosthesis and
feasibility in patients with annular calcifications.
Imaging guidance for transcatheter mitral valve inter-
ventions
TEE is generally sufficient for evaluation of the suitability
for edge-to-edge repair. Table 4 summarises the main MV
anatomical criteria used for this purpose. Patients not ful-
filling the suitability criteria may be eligible for treatment
depending on centre experience and device used.
For other (technically more complex) repair techniques
and for TMVI, ECG-gated, contrast-enhanced, cardiac
computed tomography has emerged as a complementary
imaging technique for the evaluation of patients considered
for transcatheter MV interventions. Its high spatial resolu-
tion enables precise delineation of the mitral annulus, as-
sessment of leaflets and papillary muscles anatomy, and
localisation and quantification of the extent of valve calci-
fications [29]. In addition, the identification of the circum-
flex artery and the measurement of its distance related to
the mitral annulus is critical before implantation of an an-
nuloplasty device.
Recent progress allows for the simulation of devices insert-
ed into the individual anatomy (fig. 9) in order to deter-
mine appropriate sizing, appreciate the anatomical impact
of valve intervention, and anticipate possible complica-
tions.
Several potential predictors of LVOT obstruction have
been identified [29–31]. They include both device-related
and anatomical factors:
‒ Size and mobility of the anterior mitral leaflet
‒ Dimensions of the left ventricle; bulging of the interven-
tricular septum
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Figure 8: The most important TMVI devices and their anchoring mechanism.
‒ Aorto-mitral angle (highest risk for patients with an aor-
to-mitral angle <90°)
‒ Device protrusion and device flaring
These factors combine to form the “neo-LVOT” [30],
which may differ significantly from the native one with re-
spect to shape, area and perimeter. Whereas an insignif-
icant increase of the blood velocity in the LVOT is fre-
quently recorded after percutaneous MV replacement,
insufficient post-procedural LVOT dimensions may result
in significant obstruction requiring urgent resolution by
means of alcohol ablation, implantation of a TAVI prosthe-
sis into the LVOT, or surgical correction. Careful analysis
of the pre-procedural images may be able to prevent the
occurrence of such complications.
Table 3: Early results of the most important transcatheter mitral valve replacement systems
TIARA CARDIAQ INTREPID FORTIS* TENDYNE Caisson HighLife Sapien M3
N 58 13 50 13 100 19 15 10
Access transapical transseptal transapical transapical transapical transseptal transapical transseptal
Mean age, years 73 NR 73 71 75 81 (median) 69 74
FMR/MMR, % 90 69 72 92 90 57 73 NR
LVEF, % 36±9 40 43±12 34±9 47±10 46±11 38 38
STS-PROM, % 8.6±7.2 NR 6.4±5.5 7.2±3.6 7.9±5.7 8.3±3.5 NR 4.9
Successful implan-
tation, n (%)
55 (95) 12 (92) 48 (98) 10 (77) 97 (97) 15 (79) 14 (93) 10 (100)
30-day mortality, % NR NR 14 38 6 13 21 0
Residual MR more
than mild, n (%)
0 NR 0 0 0 0 0 2 (20)
* Program aborted; N: number of patients; NR: not reported; LVEF: left ventricular ejection fraction; FMR: functional mitral regurgitation; MMR: mixed mitral regurgitation; STS-
PROM: Society of Thoracic Surgeons Predicted Risk of Mortality; MR: mitral regurgitation.
Table 4: Principal MV anatomical criteria used for evaluating feasibility of edge-to-edge repair
Suitable Unsuitable
Valve disease Prolapse or flail width <15 mm or gap <10 mm Leaflet perforation or cleft
Calcifications No or mild leaflet calcification outside of the grasping zone; annular calcification Severe calcification in the grasping zone
Mitral valve area ≥3-4 cm2 Mitral valve area <3 cm2 or baseline mean gradient
≥5 mmHg
Leaflet mobility Mobile length of the posterior leaflet ≥7 mm Mobile length of the posterior leaflet <5 mm;
rheumatic valve disease
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Figure 9: Valve simulation and assessment of neo-LVOT in a candidate for valve-in-MAC implantation. A: Valve simulation into the native
anatomy for valve sizing and assessment of the relationship to LVOT and aortic annulus; B: Cross-section through the LVOT (yellow dashed
line) at the level of maximal valve projection into the LVOT for prediction of the neo-LVOT area (blue surface). LA: left atrium; LV: left ventricle;
Ao: Aorta; LVOT: left ventricular outflow tract.
Conclusions
1. A high proportion of elderly patients suffer from
symptomatic, severe mitral regurgitation that is not
amenable to surgical treatment.
2. Transcatheter MV repair represents a safe and effec-
tive treatment option for inoperable or surgical high-
risk patients. Different methods focus on distinct
pathology and can be combined, allowing for individ-
ually tailored solutions.
3. Recently published results of randomised controlled
trials comparing percutaneous edge-to-edge repair us-
ing the Mitraclip with medical treatment among pa-
tients with secondary MR provide valuable guidance
regarding patient selection. Heart failure patients with
severe MR, moderate ventricular dilation and persist-
ing symptoms despite optimised medical management
(including CRT) should be offered MV repair with the
MitraClip system.
4. Transcatheter MV replacement has the potential to en-
able reproducible and effective treatment of MR. How-
ever, specific aspects regarding patient selection, as
well as the risk of valve thrombosis and LVOT ob-
struction, require further investigation.
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